Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities (Tables)

v3.21.1
Accrued Expenses and Other Liabilities (Tables)
3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued Expenses, summarized by major category, as of March 31, 2021 and December 31, 2020 consist of the following:

 

    March 31, 2021     December 31, 2020  
Payroll and incentives   $ 303     $ 1,094  
General and administrative expenses     234       280  
Research and development expenses     683       778  
Deferred revenue and other deferred liabilities *     186       643  
Total   $ 1,406     $ 2,795  

 

* At December 31, 2020, approximately $577 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $67 thousand is deferred revenue related to the Genentech Agreement. At March 31, 2021, approximately $153 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements).